The Latest Cardiac and Vascular News
MORRISVILLE, N.C., April 25, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 35,700 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). Each stock option was […]
– The CLEAR ACS trial is designed to evaluate the efficacy of NEXLIZET on short-term LDL-C lowering following those with a recent ACS event and at very high risk of recurrent CV event in a diverse patient population that is often underrepresented in clinical trials – ANN ARBOR, Mich., […]
— Visirna Therapeutics, the Joint Venture formed by Arrowhead and Vivo, received an exclusive license in Greater China to four of Arrowhead’s RNAi-based investigational cardiometabolic medicines — Vivo provided an initial investment of $60 million into Visirna — Arrowhead and Vivo both received equity ownership of Visirna, with Arrowhead being […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) […]
First use of Philips’ breakthrough CavaClear solution to help patients with embedded IVC filters, including an athlete suffering from a 16-year old penetrating filter Only FDA-cleared solution for advanced IVC filter removal safely ablates tissue and removes embedded IVC filters in first patients In the USA, estimates show more than […]
MEMPHIS, Tenn. and PEWAUKEE, Wis., April 21, 2022 /PRNewswire/ — Arrowhealth, a technology company specializing in cross-platform Remote Patient Monitoring (RPM) technology, and Lohman Technologies, creators of the hōm ecg+ announced an expansion of their partnership today. In 2021, Arrowhealth partnered with Lohman to bring hōm ecg+ into the portfolio of remote monitoring tools […]
ANDOVER, Mass., April 21, 2022 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on April 18, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 29,800 shares of its common stock […]
April 20, 2022 New research proposes a four-stage system for measuring the progression of cardiovascular disease (CAD) based on atherosclerotic plaque – not secondary symptoms of heart disease. Quantification of CAD burden and plaque type has demonstrated to be the strongest discriminant of future risk of Major Adverse Cardiac Events […]
VANCOUVER, British Columbia–(BUSINESS WIRE)–Clarius Mobile Health, one of Canada’s leading medical technology companies, has received Health Canada’s approval for its third-generation product line of high-performance handheld ultrasound scanners that wirelessly connect to the clinician’s Apple and Android smart devices with an AI-powered application. Now 30% smaller, lighter, and more affordable, […]
LAGUNA HILLS, Calif. and SHANGHAI and BOCHUM, Germany, April 21, 2022 /PRNewswire/ — Wallaby Medical (“Wallaby” or the “Company”), a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, today announced that it has acquired phenox GmbH, including phenox’s femtos GmbH (“femtos”), (together “phenox”), a German-based global innovation and technology […]
